

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 64892

Title: COVID-19 and Renal Transplantation

Reviewer's code: 00504406 Position: Editorial Board Academic degree: MD, PhD

**Professional title:** Associate Professor

Reviewer's Country/Territory: Greece

**Author's Country/Territory:** United States

Manuscript submission date: 2021-03-02

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-19 16:11

Reviewer performed review: 2021-04-26 16:48

**Review time:** 7 Days

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ Y] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ Y] Major revision [ ] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [ ] Anonymous [ Y] Onymous  Conflicts-of-Interest: [ ] Yes [ Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

## SPECIFIC COMMENTS TO AUTHORS

This is a brief review regarding covid-19 infection in renal transplantation. The authors are describing the initial results and outcomes in renal transplant recipients and the treatments used during the initial phase of the pandemic. It would be of extra value if the authors added some data regarding the possible impact of vaccination against covid-19, as there are some preliminary data as well as the concerns generated from the application of the vaccines. Regarding the potential effects of various medications used I would recommend updating the paper with a few position papers recently published and making more clear their potential benefits or proven deficiencies. It is also important to mention that regarding tocilizumab there is a risk of overimmunosuppression and flares of latent .CMV infections